ACON News & Events

Aclarion announced it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by renowned neurosurgeon, Roger Hartl, MD, the founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian. The trial is entitled "Bone Marrow Aspirate Concentrate Injection with MRI's - a Prospective Randomized Controlled Trial," conducted under IRB Protocol No. 24-09027977. The purpose of this study is to evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate injection on patient reported outcomes, intervertebral disc health, and pain biomarkers in a 2-year prospective study. The aim is to learn more about the natural history of degenerative disc disease, its causes, and inform its treatments.

Aclarion announced that its board of directors has authorized a share repurchase program of up to $2.5M of the company's outstanding common stock. Aclarion expects to execute the repurchase program over the next 12 months. The company intends to fund the repurchase program using existing cash and cash equivalents.

Aclarion announced the issuance of a U.S. patent covering its machine learning-based platform for analyzing magnetic resonance spectroscopy, or MRS, data. Aclarion's cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. The patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts.

Aclarion announced it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team. The trial is entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate for Osteoarthritis and Degenerative Disc Disease," conducted under IRB Protocol No. 22-06024915. The purpose of this initial study is to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine has an effect on patient-reported functional outcomes and pain. A subset of spine patients will also be eligible for Nociscan.